Wednesday, December 2, 2015

Climate Change Revisited



Despite the anti-science rhetoric that seems to have broad representation in the US Congress, climate change is a very real phenomenon that if unchecked will put the world's people in peril. If our collective behavior in regards to burning of fossil fuels continues unabated it will necessarily have a dramatic impart on peace and security in the world populated by future generations of human beings. The question we must pose to ourselves is, "Is this the legacy we want to leave behind?"


An example of what the future may have in store is what changes are occurring in the lives of the peoples of the Marshall Islands.

Sunday, November 15, 2015

Somatic Mutation and Cancer

Cancer is a disease that can involve any tissue in the human body.  Some cancers, of course, are more common than others such as lung cancer, colon cancer, breast cancer in women and prostate cancer in men.  What all cancers share in common is that the tissue cell involved undergoes a transformation that imparts a selective advantage to that cell allowing it divide outside the normal controls imposed upon that particular cell type.  This process is known as clonal expansion.

It is now clearly understood that this selective advantage is a direct result of somatic mutation of the affected cell’s genetic material – DNA.  This causal relationship was first suspected in 1914 when it was observed that chromosomal abnormalities were present in cancer cells.  Note that this discovery was made even before DNA was known to be substance responsible for carrying hereditary information.    Considerably later, it was found that introducing DNA fragments from a malignant cell into a healthy one led to transformation of the recipient cell into a cancerous one.  Soon after this finding, oncogenes were discovered.  Oncogenes are the result of mutations in a class of genes responsible for cell growth or its modulation as is the case with tumor suppressor genes.

In nature, somatic mutations are common and are harmless for the most part – they do not generally impact genes that are involved in cellular process that would impart a selective advantage to the cell type affected.  These innocuous changes are referred to as “passenger mutations.”  Those rare mutations that do provide a selective advantage to the affected cell are referred to as “driver mutations.”  Ii is this type of mutation chat can lead to cancer – the production of a clone of cells that has the capacity to function autonomously and thereby no longer constrained by the controls normally imposed upon cells of a particular tissue.

Although this evolution of a cell from a normal state to one that is cancerous has been understood in general terms, the underlying process has not been amenable to discovery until the advent of high-throughput DNA sequencing. 

Utilizing this technology, the cancer-associated genes from over 10,000 human subjects have been sequenced along with over 2500 complete genomes from cancerous tissue samples.  Dr. Inigo Marincorena and associate from the Wellcome Trust Sanger Institute in Cambridge, UK have reviewed some of the result obtained from this data.

From this extensive study, new cancer genes have been discovered as well as new kinds of mutational events.    Mutations occur as a result of a number of possible factors.  These include:
  • DNA replication errors
  • DNA damage that is subsequently incorrectly repaired by the normal DNA repair machinery or damage that is left unrepaired
  • DNA damage that is a result of exogenous factors such as mutagens, ultraviolet light and ionizing radiation
  • DNA damage that is a result of endogenous factors such as reactive oxygen species (free radicals), aldehydes or mitotic errors
  • Viruses and endogenous retrotransposons that lead to insertions into the genome.

It seems that the frequency of mutations found in various cancerous cell types vary depending upon the tissue involved.  For example, pediatric brain tumors and various types of leukemia have the lowest numbers of mutations whereas lung and skin cancers show the highest rates.  Furthermore these mutation rates can be greatly enhance if there is definitive loss of DNA repair pathways.

One of the conclusions drawn from the extensive genomic data derived from these studies is that more than one driver mutation is required in order for a clone originating from a transformed cell to successfully evolve into the fully cancerous state with the capability of metastasis.

This report represents a brief and limited overview of the extensive of this work and its significance.  It is fair to say, that future studies of this magnitude will shed greater light on the complex processes that are involved in cellular transformation and oncogenesis.

Thursday, November 5, 2015

Climate Change – An Urgent Call to Action


Humanity does not seem to grasp the dim future that awaits the entire species if the dire warnings issued by climate scientists worldwide are not heeded regarding the absolute necessity to significantly diminish the burning of fossil fuels and thereby slow down the inexorable increase of the concentration of greenhouse gases in the atmosphere.

Ironically, human families work diligently towards fashioning a better life for their children, grandchildren and future descendants, yet their focus has been tilted towards material success and enhanced prosperity.  These are important goals.  However, if this onward rush towards greater and greater prosperity is not tempered by reality, the insidious consequences of climate change will make a significant portion of the planet essentially uninhabitable and rising seas will inundate the habitats of hundreds of millions of human populations wreaking havoc upon centers of economic power where great stores of human wealth reside.  Under such circumstances, such wealth would immediately be rendered quite meaningless.

It is quite absurd at this juncture to argue the merits of the science or allow short-term economic interests to resist the necessity for immediate and significant action.  If we do not act quickly as a world community, our descendants will find themselves marooned on what would increasingly become a hostile planet.  Is this the kind of future we are working so assiduously towards?


Obfuscation and resistance serves no useful purpose – the longer we procrastinate the more impossible it will be to make meaningful corrections on this our spaceship earth.

Tuesday, October 6, 2015

Use of Genetically Modified Yeast in the Production of Opiates

Opiates are pain-relieving drugs that play a vital role in palliative care.  Morphine is a well-known member of this class of compounds.  Opiates have been derived from poppy plants for thousands of years.  The compound thebaine (paramorphine or codeine methyl enol ether) - see structure below -is the natural product that is the precursor for opiates.



Thebaine

Due to the incredible strides that have been made in regards to genetic engineering, a team of researchers headed by Christina Smolke from Stanford University in Palo Alto California has successfully incorporated genes derived from a variety of plants including poppies, bacterial genes from Pseudomonas and rodent genes into the yeast genome and endowed these modified yeast organisms with the capacity to produce thebaine from a sugar source.  This methodology required the successful incorporation of 21 different genes – a monumental enterprise.


This is a significant breakthrough in the area of synthetic biology for it suggests that eventually it will become possible to readily produce large quantities of thebaine that can subsequently be used to produce a variety of opiates.  Smolke and her colleagues avoided producing a modified yeast cell capable of producing morphine directly from sugar in order to forestall the possibility of inadvertently making the illicit production of morphine a practical reality.

Friday, October 2, 2015

The Role of Neutrophils in Guiding the Immune Response to Infection by the Influenza Virus

The influenza is virus has a global impact on human populations. Much research effort has been directed towards understanding how the human immune system combats influenza virus infection. The cellular target of this virus is the epithelial cells of the respiratory tract. In order for the immune system to successfully combat this pathogen, virus specific cytotoxic CD8+ circulating lymphocytes must migrate to the site of infection.

 It has been established that in order for these cytotoxic CD8+ lymphocytes to successfully kill virally-infected cells, it must be preceded by the innate immune response. A key player in this first response are Neutrophils (see image below) These cells are generally the first cell type to cross the blood vessel epithelium into the distressed tissue and are responsible for generating chemical signals that alert different types of immune cells.



 Although this relationship between Neutrophils and aspects of the adaptive immune response has been established, the underlying molecular mechanisms have been unclear. Dr. Kihong Lim and his colleagues at the Department of Microbiology and Immunology, David H. Smith Center for Vaccine Biology and Immunology, University of Rochester, Rochester, NY have investigated the mechanism of this immune response to infection by the influenza virus. What they uncovered was an interesting process.

Their studies have shown that the subset of cytotoxic CD8+ lymphocytes specific for influenza infected epithelium cells is dependent upon the presence of Neutrophils at the site of infection. The migrating Neutrophils leave in their wake a chemical trail; that chemical is a particular chemokine – a class of substances that serves as a powerful attractant to circulating lymphocytes – CXCL12. It is this CXCL12 that is a necessary requirement for the procurement of virus specific CD8+ lymphocytes at the infection site and for their subsequent ability to kill infected respiratory epithelial cells.

The results of this work contribute significantly to the fundamental understanding of the complex interactions that are required to mount a successful immunological assault upon a virus-induced infection.

Thursday, September 24, 2015

Progress in Developing a Vaccine against the Ebola Virus

Progress in Developing a Vaccine against the Ebola Virus
The recent spread of hemorrhagic fever (EHF) in areas of West Africa including Guinea, Sierra Leone and Liberia has placed considerable urgency on the need to develop an effective vaccine against the pathogen responsible for this horrific and highly contagious disease, the Ebola virus (EBOV).  To date, of the approximately 27,200 reported cases, there have been more than 11,100 deaths – a mortality rate of  40.8 percent.   EBOV is so infectious that a high incidence rate has also been reported among health care workers.  It needs to be kept in mind that the health care infrastructure of the countries affected has been severely compromised especially since these so-called, “low resource” countries have budgets inadequate to respond effectively to this challenge.

By way of background EBOV belongs to a class of viruses called filoviruses.   Filoviruses are single-stranded RNA viruses.  This class of viruses possesses a glycoprotein (GP) on its surface that could conceivably make a good candidate as an immunogen – a protein capable of eliciting an immune response.

Dr. Andrea Marzi at the Laboratory of Virology, Division of Intramural Research at the National Institute of Allergy and Infectious Diseases  at the National Institutes of Health in Hamilton Montana.and his colleagues  have helped develop a strategy for developing such a vaccine.  The strategy they employed can be outlined in the following way –
  • A live attenuated stomatitis virus was employed as a viral vector
  • Recombinant technology was employed to modify this virus so that it expresses the Ebola GP on its surface referred to as Viral Stomatitis Vector EBOV (VSV-EBOV)
  • This viral vector was then introduced into experimental animals – the rodent and macaque.

This approach was shown to be highly efficacious in both pre and post exposure vaccinations.  These results were so promising that phase 1 clinical trials in humans  were begun in several  worldwide locations. 

The following is in the author’s own words – “Complete and partial protection was achieved with a single dose given as late as 7 and 3 days before challenge, respectively.  This indicates that VSV-EBOV may protect humans against EBOV infections in West Africa with relatively short time to immunity, promoting its use for immediate public health responses.”

Wednesday, September 2, 2015

Tumor Suppressor p53 and the Clearance of Apoptotic Cells


Within the human body, with its complex array of highly differentiated organs and tissues, it is estimated that more than a billion cells die each day.  Most of these deaths arise from a natural process referred to as apoptosis – programmed cell death.  Since apoptosis is integral to the functioning of a healthy organism, its mechanism has been the focus of study for many years. 

In addition to the process of apoptosis, there also exists a mechanism for the efficient processing and clearance of the cellular debris that is a direct result of apoptosis.  Otherwise, the accumulation of released substances from dead cells could function as autoantigens and elicit an undesirable immune response against normal tissue resulting in autoimmune diseases.  In addition, chronic inflammation and developmental abnormalities could result from the buildup up cellular debris.  It has been established that the immune response to apoptotic cells involves the mobilization of phagocytic cells whose function is to engulf the dead or dying cells.  This process necessarily requires the expression of immune tolerance in order to prevent an autoimmune response.

The tumor suppressor  p53 protein has long been associated with the mechanism of apoptosis.  However, little has been established in regards to the putative role of p53 in the clearance of cellular debris that results from apoptosis.

Dr. Kyoung Wan Yoon and his colleagues from the Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA have focused their research efforts on the elucidation of the role of p53 in the clearance of post apoptotic cells and the establishment of tolerance to self-antigens.

What they have shown is the following.  As a result of stress upon a cell that leads to p53-mediated apoptosis, p53 triggers the production of a protein product from the so-called “Death Domain1a (DD1a)” gene.  DD1a functions as a ligand that is instrumental in the binding of the apoptotic cell to the phagocytic immune cell that will eventually engulf the dead cell.  Once this engulfment occurs it subsequently triggers the binding of an inhibitory T cell that ensures tolerance to self-antigens; thereby, preventing untoward reactions that could lead to a disease state.


This kind of work is extremely valuable in furthering the understanding of the mechanism of self-tolerance.  Such knowledge may prove instrumental in determining the underlying mechanisms involved in auto-immune disease.